1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cross fire: Daratumumab-based therapies are standard of care in newly diagnosed multiple myeloma
    Review

    Korde, N.; Usmani, S. Z.
    Hematology-Oncology and Stem Cell Therapy (2023)

    Fulltext@MSK | Save
  • Public tumor-wide neoantigens derived from clonal aberrant splicing events drive tumor-specific T-cell responses
    Meeting Abstract

    Kwok, D.; Stevers, N.; Nejo, T.; Jung, J.; Chen, L.; Lakshmanachetty, S.; Etxeberria, I.; Gallus, M.; Yamamichi, A.; Ramos, E.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Reversible Parkinsonism after BCMA-directed Car T cell administration
    Meeting Abstract

    Gewirtz, A.; Mailankody, S.; Usmani, S.; Santomasso, B.
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • TITLE: A pilot study of 89Zr-DFO-REGN3767 anti-LAG-3 antibody positron emission tomography in patients with diffuse large B-cell lymphoma
    Meeting Abstract

    Pandit-Taskar, N.; Shutian, R.; Grkovski, M.; Schwartz, J.; Lyashchenko, S.; Cheung, K.; Uldrick, T.; Ma, D.; Giurleo, J.; Palomba, L.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Post-Hoc analysis of measurable residual disease from BMT-CTN 1506/MORPHO: FLT3-ITD variant allele frequency and survival are highly correlated
    Meeting Abstract

    Levis, M. J.; Hamadani, M.; Logan, B. R.; Jones, R. J.; Singh, A. K.; Litzow, M. R.; Wingard, J. R.; Papadopoulos, E. B.; Perl, A.; Soiffer, R. J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • DNA methylation-based classification of hairy cell leukemia and splenic B cell lymphoma
    Meeting Abstract

    Yamaguchi, K.; Abdelbaky, S.; Arons, E.; Cross, M.; Wu, Y. Z.; Weigel, C.; Anghelina, M. I.; Parker, H.; Kibler, A.; Salido, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with richter transformation without prior chemoimmunotherapy for CLL/SLL: An international multicenter retrospective study
    Meeting Abstract

    Kittai, A. S.; Huang, Y.; Miller, S.; Allan, J. N.; Bhat, S. A.; Bond, D. A.; Brander, D. M.; Byrd, J. C.; Chavez, J. C.; Chong, E. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in post-cBTKi CLL/SLL: ∼30 months follow-up and subgroup analysis with/without prior BCL2i from the phase 1/2 BRUIN study
    Meeting Abstract

    Woyach, J. A.; Brown, J. R.; Ghia, P.; Roeker, L. E.; Patel, K.; Eyre, T. A.; Munir, T.; Lech-Maranda, E.; Lamanna, N.; Tam, C. S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Obecabtagene autoleucel (obe-cel, AUTO1) for relapsed/refractory adult B-cell acute lymphoblastic leukemia (R/R B-ALL): Pooled analysis of the ongoing FELIX phase Ib/II study
    Meeting Abstract

    Roddie, C.; Sandhu, K. S.; Tholouli, E.; Shaughnessy, P.; Barba, P.; Guerreiro, M.; Bishop, M. R.; Yared, J. A.; Ghobadi, A.; Yallop, D.; more...
    Blood (2023)

    Fulltext@MSK | Save